File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Risk assessment of venous thromboembolism in hematological cancer patients: a review

TitleRisk assessment of venous thromboembolism in hematological cancer patients: a review
Authors
Keywordsimmunomodulatory agents
JAK2
l-asparaginase
myeloma
myeloproliferative neoplasm
Issue Date2020
PublisherExpert Reviews Ltd.
Citation
Expert Review of Hematology, 2020, v. 13 n. 5, p. 471-480 How to Cite?
AbstractIntroduction: Venous thromboembolism (VTE) is a frequent and serious complication in cancer patients. Nonetheless, patients with hematological cancers receive less attention as compared with their solid tumor counterparts regarding this potentially fatal complication. Areas covered: Risk factors that are associated with the development of VTE in hematological cancers are discussed, based on a PubMed literature search. Since different hematological malignancies carry different risks of VTE, risk assessment in individual types of hematological cancers, including acute leukemias, lymphomas, myeloma, and myeloproliferative neoplasms are examined separately. Clinical relevance of VTE assessment and current guidelines on thromboprophylaxis in patients with hematological malignancies are also briefly reviewed. Expert opinion: When assessing VTE risk in patients with hematological cancers, in addition to the non-cancer specific risk factors, individual cancer-type-specific and the therapy-related factors must be taken into consideration. Primary thromboprophylaxis should be considered in high-risk patients. © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.
Persistent Identifierhttp://hdl.handle.net/10722/289777
ISSN
2019 Impact Factor: 2.573
2015 SCImago Journal Rankings: 1.059
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, TSY-
dc.contributor.authorHwang, YY-
dc.contributor.authorTse, E-
dc.date.accessioned2020-10-22T08:17:19Z-
dc.date.available2020-10-22T08:17:19Z-
dc.date.issued2020-
dc.identifier.citationExpert Review of Hematology, 2020, v. 13 n. 5, p. 471-480-
dc.identifier.issn1747-4086-
dc.identifier.urihttp://hdl.handle.net/10722/289777-
dc.description.abstractIntroduction: Venous thromboembolism (VTE) is a frequent and serious complication in cancer patients. Nonetheless, patients with hematological cancers receive less attention as compared with their solid tumor counterparts regarding this potentially fatal complication. Areas covered: Risk factors that are associated with the development of VTE in hematological cancers are discussed, based on a PubMed literature search. Since different hematological malignancies carry different risks of VTE, risk assessment in individual types of hematological cancers, including acute leukemias, lymphomas, myeloma, and myeloproliferative neoplasms are examined separately. Clinical relevance of VTE assessment and current guidelines on thromboprophylaxis in patients with hematological malignancies are also briefly reviewed. Expert opinion: When assessing VTE risk in patients with hematological cancers, in addition to the non-cancer specific risk factors, individual cancer-type-specific and the therapy-related factors must be taken into consideration. Primary thromboprophylaxis should be considered in high-risk patients. © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.-
dc.languageeng-
dc.publisherExpert Reviews Ltd.-
dc.relation.ispartofExpert Review of Hematology-
dc.rightsExpert Review of Hematology. Copyright © Expert Reviews Ltd.-
dc.subjectimmunomodulatory agents-
dc.subjectJAK2-
dc.subjectl-asparaginase-
dc.subjectmyeloma-
dc.subjectmyeloproliferative neoplasm-
dc.titleRisk assessment of venous thromboembolism in hematological cancer patients: a review-
dc.typeArticle-
dc.identifier.emailChan, TSY: drtchan@hku.hk-
dc.identifier.emailHwang, YY: yyhwang@hku.hk-
dc.identifier.emailTse, E: ewctse@hku.hk-
dc.identifier.authorityTse, E=rp00471-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1080/17474086.2020.1751608-
dc.identifier.pmid32249620-
dc.identifier.scopuseid_2-s2.0-85083512320-
dc.identifier.hkuros317059-
dc.identifier.volume13-
dc.identifier.issue5-
dc.identifier.spage471-
dc.identifier.epage480-
dc.identifier.isiWOS:000531057700003-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl1747-4094-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats